GGrantIndex
← Search

BEVACIZUMAB/CETUXIMAB/IRINOTECAN OR BEVACIZUMAB/CETUXIMAB IN COLORECTAL CANCER

$22,446M01FY2006RRNIH

New York University School Of Medicine, New York NY

Investigators

Linked publications & trials

View original record on NIH RePORTER →